This new discovery triggered the applause of a room full of oncologists, researchers and industrialists, gathered in Paris for the annual congress of the European Society of Medical Oncology. Presented this September 11, 2022, the study showed that the combination of two immunotherapy treatments could produce a response rate “unprecedented” and so shrink the tumor by 95%according to Myriam Chalabi, lead author of the study and researcher at the Netherlands Cancer Institute in Amsterdam.
The current treatment offered to patients with Colon Cancer is surgery, which may or may not be followed by chemotherapy. In this study, patients were treated with a series of immunotherapy and then operated on one to two weeks later. Although it was conducted on a small number of patients, 112 in total, the results are more striking: after examination, 95% of the tumors regressed by 90% and 99% of the tumors regressed by more than 50%. Currently, conventional chemotherapy offers a less interesting therapeutic response: only 5 to 7% of tumors regress by more than 50%.
However, this progress concerns only 10 to 15% of non-metastatic colon cancerscancers with a genome abnormality leading to a failure of the DNA repair system (dMMR). A third of these abnormalities are linked to a hereditary disease, (…)
Gynecological violence: what do we have the right to refuse at the gynecologist?
COVID FRANCE FIGURES. This Tuesday, September 13, 2022: case, the news of the day live
Covid symptoms (September 2022) BA.5: duration, incubation, list
Twenty children die in Gambia after taking cough syrup
Blood test could detect 50 types of cancer, even before symptoms appear